AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I study titled A Phase I, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AZD1163 Administered as Single and Multiple Ascending Doses in Healthy Volunteers. The study aims to assess the safety and tolerability of the drug AZD1163, administered both intravenously and subcutaneously, in healthy participants. This study is significant as it represents the first human trial of AZD1163, potentially paving the way for future therapeutic applications.
The intervention being tested is AZD1163, a biological treatment administered through intravenous (IV) infusion and subcutaneous (SC) injection. The purpose of AZD1163 is to evaluate its safety and tolerability in humans, which is crucial for its potential development into a viable medical treatment.
The study follows an interventional design, with participants randomly allocated to receive either the active drug or a placebo. It employs a sequential intervention model and triple masking, meaning that the participant, care provider, and investigator are unaware of the treatment allocation. The primary purpose of the study is treatment-focused, aiming to gather initial safety and tolerability data.
The study began on November 1, 2023, with an actual start date, and the latest update was submitted on June 23, 2025. These dates are important as they provide a timeline for the study’s progress, indicating that it is currently active but not recruiting new participants.
The update on this clinical study could influence AstraZeneca’s stock performance by providing investors with insights into the company’s research and development pipeline. Positive results could boost investor confidence and potentially increase stock value, while any setbacks might have the opposite effect. As AstraZeneca competes in a dynamic pharmaceutical industry, advancements in their clinical trials are closely watched by investors and competitors alike.
The study is ongoing, with further details available on the ClinicalTrials portal.